76 results
S-1/A
EX-10.5.5
CADL
Candel Therapeutics Inc
16 Jul 21
IPO registration (amended)
6:07am
termination (not including death or Disability) without Cause (as defined below) or due to your voluntary termination with Good Reason (as defined below … without any breach of this Agreement under the following circumstances:
(a) Death. The Executive’s employment hereunder shall terminate upon his death
S-1/A
EX-10.2
CADL
Candel Therapeutics Inc
16 Jul 21
IPO registration (amended)
6:07am
on or after the grantee’s death. Any such designation shall be on a form provided for that purpose by the Administrator and shall not be effective until … separation from service, or (ii) the grantee’s death, but
only to the extent such delay is necessary to prevent such payment from being subject
S-1/A
EX-10.5.4
CADL
Candel Therapeutics Inc
16 Jul 21
IPO registration (amended)
6:07am
employment terminates due to an involuntary termination (not including death or Disability) without Cause (as defined below) or due to Executive’s … . The Executive’s employment hereunder may be terminated without any breach of this Agreement under the following circumstances:
(a) Death
S-1/A
EX-10.5.1
xe1792
16 Jul 21
IPO registration (amended)
6:07am
10-K
EX-10.12
nls1xt zxj4o
29 Mar 22
Annual report
8:46am
S-1/A
EX-3.2
sc24v6yx8wp7b4w w8
16 Jul 21
IPO registration (amended)
6:07am
8-K
EX-3.1
haych80ysl0c7d6
30 Jul 21
Departure of Directors or Certain Officers
12:00am
S-1/A
EX-10.5.3
cd4b9w2s
16 Jul 21
IPO registration (amended)
6:07am
S-1/A
EX-10.5.2
ozlknl4b0ksd ni
16 Jul 21
IPO registration (amended)
6:07am
8-K
EX-99.1
h1u1recch
19 May 23
Regulation FD Disclosure
9:15am
S-1/A
EX-10.1
fv0074vcjjaa
16 Jul 21
IPO registration (amended)
6:07am
8-K
EX-99.1
egz2k0h c2kwehi
6 Nov 23
Candel Therapeutics Announces Initial Positive Interim Data from Randomized Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer
8:15am
8-K
csvw s3hnbzr2
29 Jun 23
Submission of Matters to a Vote of Security Holders
8:31am
8-K
EX-99.1
62g9w96v5 z7w4xe
17 Aug 21
Other Events
4:41pm
8-K
sizaxejzzmhzzflzsx8u
14 Oct 22
Submission of Matters to a Vote of Security Holders
5:00pm
8-K
EX-99.1
utkpg
1 Mar 22
Candel Therapeutics Announces $25 Million Non-dilutive Debt Financing Agreement with Silicon Valley Bank
8:09am
8-K
EX-99.1
oqmc58sf5k4ibgan25
9 Feb 22
Candel Therapeutics Appoints Dr. Francesca Barone as Chief Scientific Officer
8:05am